Xeris Pharmaceuticals

General Information


We are a specialty pharmaceutical company leveraging our novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. We have developed a ready-to-use, room-temperature stable liquid glucagon formulation that, unlike any currently available products, can be administered without any preparation or reconstitution. Our lead product candidate, Glucagon Rescue Pen, delivers ready-to-use glucagon via a commercially-available auto-injector for the treatment of severe hypoglycemia, a potentially life-threatening condition, in people with diabetes.


Employees: 55
Founded: 2005
Contact Information
Address 180 N. LaSalle Street, Suite 1810, Chicago, IL 60601, US
Phone Number 1-844-445-5704
Web Address http://www.xerispharma.com
View Prospectus: Xeris Pharmaceuticals
Financial Information
Market Cap $296.0mil
Revenues $1.4 mil (last 12 months)
Net Income $-33.8 mil (last 12 months)
IPO Profile
Symbol XERS
Exchange NASDAQ
Shares (millions): 5.7
Price range $15.00 - $15.00
Est. $ Volume $85.5 mil
Manager / Joint Managers Jefferies/ Leerink Partners/ RBC Capital Markets
CO-Managers Mizuho Securities
Expected To Trade: 6/21/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change